KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBITDA: 2010-2024

Historic EBITDA for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $81.7 million.

  • Supernus Pharmaceuticals' EBITDA fell 247.46% to -$60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.9 million, marking a year-over-year decrease of 162.33%. This contributed to the annual value of $81.7 million for FY2024, which is 1649.93% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported EBITDA of $81.7 million as of FY2024, which was up 1,649.93% from -$5.3 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' EBITDA peaked at $173.7 million during FY2020, and registered a low of -$5.3 million during FY2023.
  • Moreover, its 3-year median value for EBITDA was $46.1 million (2022), whereas its average is $40.8 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' EBITDA plummeted by 111.42% in 2023 and then soared by 1,649.93% in 2024.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' EBITDA stood at $173.7 million in 2020, then crashed by 50.47% to $86.0 million in 2021, then tumbled by 46.39% to $46.1 million in 2022, then tumbled by 111.42% to -$5.3 million in 2023, then spiked by 1,649.93% to $81.7 million in 2024.